86 PicconiB.PisaniA.BaroneI.BonsiP.CentonzeD.BernardiG.et al (2005)
The medication slows gastric emptying, increases satiety signaling in the hypothalamus, and enhances insulin secretion in response to glucose, addressing multiple metabolic pathways simultaneously
This change affects the Health Partners (Medicaid) and KidzPartners (CHIP) plans
First, it acts to boost your satiety inside the brain's hunger center (postrema and hypothalamus), then it delays your gastric emptying, slowing the rate at which food leaves the stomach
Whether you are considering semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), clinical trial data offers helpful benchmarks, though individual results vary significantly